1. Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan.
- Author
-
Yamagishi Y, Nishiyama N, Koizumi Y, Matsukawa Y, Suematsu H, Hagihara M, Katsumata K, and Mikamo H
- Subjects
- Europe, Fidaxomicin, Humans, Japan, Microbial Sensitivity Tests methods, North America, Taiwan, Aminoglycosides pharmacology, Anti-Infective Agents pharmacology, Clostridioides difficile drug effects, Clostridium Infections drug therapy
- Abstract
We evaluated the susceptibility of 100 Japanese Clostridium difficile isolates to fidaxomicin, a new macrocyclic antibiotic. The minimum inhibitory concentration (MIC) range of fidaxomicin was 0.03-0.5 μg/mL, with a MIC for inhibition of 50% (MIC
50 ) of 0.12 μg/mL, and for inhibition of 90% (MIC90 ) of 0.25 μg/mL. We also evaluated the susceptibilities of the same 100 C. difficile isolates to vancomycin, metronidazole, moxifloxacin, clindamycin, meropenem, and ampicillin. Of all the antibiotics tested, fidaxomicin showed the most potent antimicrobial activity against this group of C. difficile isolates. MIC levels against C. difficile isolates, including those producing binary toxin, did not substantially differ from those previously reported in Europe, North America and Taiwan., (Copyright © 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF